Léa Sorret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Léa Sorret has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Mattias Paulsson
Department of Women's and Children's Health Uppsala University Uppsala Sweden
3 shared publications - Giorgia De Paoli
School of Health Sciences, University of Dundee, Dundee, United Kingdom
2 shared publications Jörg Huwyler
Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
2 shared publications- Lara Nonis
Pharmaceutical Development, Lonza AG, Hochbergerstrasse 60G, CH-4057, Basel, Switzerland
2 shared publications Markus Kardorff
Drug Product Services, Lonza AG, Hochbergerstrasse 60G, 4057 Basel, Switzerland; Division of Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland
2 shared publications- Nathalie Fuentes
Dosage Form Design and Development, BioPharmaceutical Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations
Antibody–drug conjugates (ADCs) combine the target specificity of monoclonal antibodies with the potency of cytotoxic small molecules, offering enhanced therapeutic potential. However, their inherent structural complexity, arising from the interplay of antibody, linker, and payload, introduces unique challenges for drug product (DP) development, stability, and scalability requiring tailored approaches to maintain the quality target product profile throughout the product lifecycle. This review summarizes key formulation and process development considerations for ADCs, with an emphasis on aspects that are particularly distinctive for ADC drug products. Critical degradation risks, such as photo- and heat-induced degradation, are discussed in the context of formulation screening, formulation excipients and primary packaging selection, and DP process design. Basic considerations on analytical tools used to identify and monitor critical quality attributes are provided. Lyophilization strategies, essential for the stability of commercialized ADCs, are recommended using Design of Experiments and modeling approaches. Furthermore, robust DP process control strategies during scale-up are reviewed with a focus on lyophilization, the application of Quality by Design (QbD) principles, and risk-based methodologies to address ADC‑specific challenges. Finally, the review explores the transition from early development to late-phase clinical and commercial stages, underscoring the need for evolving control strategies. Overall, it provides an overview of current practices and challenges in ADC formulation and DP process development, offering strategies to navigate these complexities based on literature and insights from approved ADCs.
- 4 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Open AccessAntibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations
Antibody–drug conjugates (ADCs) combine the target specificity of monoclonal antibodies with the potency of cytotoxic small molecules, offering enhanced therapeutic potential. However, their inherent structural complexity, arising from the interplay of antibody, linker, and payload, introduces unique challenges for drug product (DP) development, stability, and scalability requiring tailored approaches to maintain the quality target product profile throughout the product lifecycle. This review summarizes key formulation and process development considerations for ADCs, with an emphasis on aspects that are particularly distinctive for ADC drug products. Critical degradation risks, such as photo- and heat-induced degradation, are discussed in the context of formulation screening, formulation excipients and primary packaging selection, and DP process design. Basic considerations on analytical tools used to identify and monitor critical quality attributes are provided. Lyophilization strategies, essential for the stability of commercialized ADCs, are recommended using Design of Experiments and modeling approaches. Furthermore, robust DP process control strategies during scale-up are reviewed with a focus on lyophilization, the application of Quality by Design (QbD) principles, and risk-based methodologies to address ADC‑specific challenges. Finally, the review explores the transition from early development to late-phase clinical and commercial stages, underscoring the need for evolving control strategies. Overall, it provides an overview of current practices and challenges in ADC formulation and DP process development, offering strategies to navigate these complexities based on literature and insights from approved ADCs.
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- 27 May 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Safe Handling and Clinical Administration of Antibody Drug Conjugates: Occupational Safety, Material Compatibility, and the Integration of CSTDs into Workflows
Antibody-drug conjugates (ADCs) represent a rapidly expanding class of therapeutics, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. Their increasing clinical adoption introduces complex challenges for safe handling, preparation, and administration that extend beyond traditional hazardous drug and monoclonal antibodies - based therapies protocols. These inherent complexities of ADCs necessitate strict controls during handling and administration. This review outlines the current regulatory frameworks and institutional practices guiding ADC's in-use handling and highlights key limitations within these practice systems. We examine current handling practices, including the regulatory and institutional guidance landscape, engineering controls, aseptic compounding environments, and the use of personal protective equipment (PPE), as well as the integration of closed system transfer devices (CSTDs) into clinical and pharmacy workflows. This paper addresses ADC dosing solution stability and administration material compatibility, highlighting risks such as undesired interaction with IV bag materials, tubing, and other administration components while identifying potential gaps in compatibility information availability and accessibility. In addition, the effectiveness of closed-system transfer devices (CSTDs) and their implementation into the clinical workflow are discussed. Finally, we provide recommendations to address the identified gaps to promote safer, more consistent clinical handling practices. Given the complexity of ADC products, the rise of novel ADC constructs, and their expanding application in targeted therapies and alternative administration routes, continued ADC-specific research and regulatory guidance will be essential to achieve safe and effective clinical implementation.
- Open Access
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Multidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals
- 19 March 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (5) , 104253
Open AccessMultidisciplinary exploratory survey: Initial insights into biologic drug handling and regulatory perspectives among healthcare professionals
- Open Access
- 27 May 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2055-2064
Impact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity
- 27 May 2024
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 113 (8) , 2055-2064
Open AccessImpact of Post Manufacturing Handling of Protein-Based Biologic Drugs on Product Quality and User Centricity
- 15 May 2024
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (3) , 1-10
Impact on Quality during In-Use Preparation of an Antibody Drug Conjugate with Eight Different Closed System Transfer Device Brands
The aim of this study was to investigate the in-use compatibility of eight commercially available closed system transfer device brands (CSTDs) with a formu
- 15 May 2024
- Published by Springer Nature in The AAPS Journal
- Vol. 26 (3) , 1-10
Impact on Quality during In-Use Preparation of an Antibody Drug Conjugate with Eight Different Closed System Transfer Device Brands
The aim of this study was to investigate the in-use compatibility of eight commercially available closed system transfer device brands (CSTDs) with a formu
- 7 February 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (6) , 1681-1686
Cryoprotection in Human Mesenchymal Stromal/Stem Cells: Synergistic Impact of Urea and Glucose
- 7 February 2023
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 112 (6) , 1681-1686
Cryoprotection in Human Mesenchymal Stromal/Stem Cells: Synergistic Impact of Urea and Glucose